Andrew Zhu

Andrew Zhu at Massachusetts General Hospital is a world leader in hepatobiliary oncology who has contributed to pivotal trials in biliary tract cancer including immunotherapy-based regimens. His research has advanced understanding of biliary tract cancer biology and defined systemic treatment approaches across hepatocellular carcinoma and cholangiocarcinoma. He contributed to the TOPAZ-1 trial design and evaluation that established durvalumab plus gemcitabine-cisplatin as first-line standard of care in advanced biliary tract cancer. His laboratory work has characterized molecular features of BTC and their relationship to immunotherapy response.